Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?

Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?

Blog Article

Chronic liver disease (CLD) alters normal hemostatic and thrombotic systems via multiple mechanisms Golf Ball including reduced platelet function and number, leading to challenging peri-operative planning.Hepatic thrombopoietin (TPO) synthesis is reduced in CLD, leading to several recent randomized, placebo-controlled trials examining the utility of TPO-mimetics to increase platelet counts prior to surgery.While these trials do suggest that TPO-mimetics are efficacious at increasing platelet counts in patients with CLD and have led to several recent drug approvals in this space by the U.

S.Food & Drug Administration, it remains unclear whether these results translate to the relevant clinical Mini Backpacks endpoint of reduced perioperative bleeding rate and severity.In this article, we review several recently-published, phase 3 trials on the TPO-mimetics eltrombopag, avatrombopag and lusutrombopag, and discuss the clinical significance of their results.